Verona Pharma PLC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Verona Pharma's 10-K filing summarizes the company's financial performance for 2024, emphasizing the FDA approval and commercial launch of Ohtuvayre, along with ongoing clinical development programs.
Verona Pharma plc filed its 10-K for the year ended December 31, 2023, outlining details of its share capital, American Depository Shares (ADS), and corporate governance.